Pricing Log in Create free account

Geron Corporation (GERN) vs Kura Oncology, Inc. (KURA)

Geron Corporation and Kura Oncology, Inc. are both Biotechnology companies. Geron Corporation and Kura Oncology, Inc. are of similar size ($610.4M and $604.9M). Geron Corporation has the higher net margin (−22.0% vs −384.3%) and the lower return on invested capital (−34.1% vs 0.00%). Across the 16 metrics below, Geron Corporation leads on 11 and Kura Oncology, Inc. on 5.

Valuation

Metric GERN KURA Biotechnology median
P/E n/m n/m 10.60
P/S 3.03 8.31 9.40
P/B 2.91 13.25 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 2.59 1.71 9.02
Earnings yield (7.49%) (46.68%) (32.88%)
Free cash flow yield (13.84%) (18.30%) (23.13%)

Profitability

Metric GERN KURA Biotechnology median
Gross margin 91.59% 99.35% 68.51%
Operating margin (14.75%) (411.90%) 0.00%
Net margin (21.99%) (384.30%) 0.00%
Free cash flow margin (41.91%) (152.06%) 0.00%
Return on equity (20.12%) (167.71%) (51.96%)
Return on assets (8.74%) (46.73%) (46.06%)
Return on invested capital (34.12%) 0.00% 0.00%

Growth

Metric GERN KURA Biotechnology median
Revenue growth (TTM) 18.60% — 6.76%
EPS growth (last fiscal year) 51.85% (57.43%) 29.88%
Revenue growth, 5-year CAGR 273.49% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GERN KURA Biotechnology median
Debt to equity 0.53 0.20 0.00
Current ratio 6.31 4.73 4.97
Net debt to EBITDA 3.28 2.11 1.01

Dividend

Metric GERN KURA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GERN KURA Biotechnology median
Market cap 610.41m 604.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack